<DOC>
	<DOCNO>NCT00800462</DOCNO>
	<brief_summary>This phase IV , double-blind , multicenter , randomize trial evaluate efficacy safety two M3 receptor antagonist ( Trospium Chloride Darifenacin Hydrobromide ) one standard drug ( Oxybutynin Chloride ) treatment overactive bladder individual spinal cord injury .</brief_summary>
	<brief_title>Comparative Study Efficacy Safety Muscarinic M3 Receptors Antagonists Treatment Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description />
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Male female patient , 18 75 year age . Female patient childbearing potential* must negative urine pregnancy test result day Screening Visit practice reliable method contraception** *A female consider childbearing potential unless : Postmenopausal least 12 month prior study drug administration ; Without uterus and/or ovary ; Has surgically sterilize least 6 month prior study drug administration . **Reliable method contraception include : Hormonal method intrauterine device use least 30 day prior study drug administration ; Barrier method plus spermicidal use least 14 day prior study drug administration ; Sexual abstinence lifestyle . 2 . Patients neurogenic bladder detrusor overactivity secondary spinal cord injury . Patients urinary incontinence ( minimum one occurrence per day ) despite current treatment . [ NOTE : Bladder empty may accomplish straining , intermittent catheterization ( IC ) , spontaneous micturition leakage episode . ] 3 . Patients serum creatinine within normal limit normal renal function 4 . Patients stable dose ( minimum one month ) concomitant medication Neurogenic detrusor overactivity 5 . Patients must adequate cognitive function understand requirement study , include complete questionnaire sign write Informed Consent . 1 . Female patient pregnant ( positive urine pregnancy test ) , plan become pregnant study period , breastfeeding , childbearing potential practicing reliable method birth control . 2 . Patients history transurethral sphincterotomy , bladder neck prostatic resection , previous bladder surgery include myomectomy augmentation cystoplasty . 3 . Patients chronic indwell catheter . 4 . Patients , opinion Investigator , unstable stable multiple sclerosis . 5 . Patients know , uncontrolled systemic disease . 6 . Patients evidence recent alcohol/drug abuse . 7 . Patients urinary retention , gastrointestinal obstructive disorder uncontrolled narrowangle glaucoma . 8 . Patients contraindication Trosec™ , Enablex™ Uromax® . 9 . Patients , opinion Investigator , significant condition situation may put patient significant risk , confound study result , interfere significantly patient 's participation study . 10 . Patients history poor cooperation , noncompliance , unreliability . 11 . Patients currently participate investigational drug study participate investigational drug study within 30 day Screening Visit . 12 . Patients administer anticholinergic and/or antispasmodic drug course study . 13 . Patient hepatic insufficiency . 14 . Patient administer intravesical botulinum toxin within 6 month prior Screening Visit and/or expect receive intravesical botulinum toxin course study . 15 . Patient medical condition would interfere interpretation study result conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>